Jiangsu Hengrui Medicine Co., Ltd

🇺🇸United States
Ownership
-
Established
1970-01-01
Employees
-
Market Cap
$38.9B
Website
http://www.hrs.com.cn/english/
Clinical Trials
Related News

The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients

First Posted Date
2015-02-19
Last Posted Date
2015-02-19
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
168
Registration Number
NCT02366377

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2015-02-18
Last Posted Date
2019-01-18
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
18
Registration Number
NCT02364362
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, China

The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: SHR3824
Drug: Placebo
First Posted Date
2015-02-11
Last Posted Date
2015-02-11
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
48
Registration Number
NCT02361138
Locations
🇨🇳

Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer

First Posted Date
2015-02-11
Last Posted Date
2018-07-09
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
38
Registration Number
NCT02361112
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2015-02-06
Last Posted Date
2019-11-04
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
137
Registration Number
NCT02356991
Locations
🇨🇳

Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China

🇨🇳

Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China

The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: SHR3824
Drug: Placebo
First Posted Date
2015-02-05
Last Posted Date
2015-02-05
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
84
Registration Number
NCT02356224
Locations
🇨🇳

Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: SHR3824
First Posted Date
2015-02-03
Last Posted Date
2015-02-03
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
12
Registration Number
NCT02353975

The Drug-drug Interaction of SHR3824 and Metformin

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: SHR3824 metformin
First Posted Date
2015-02-03
Last Posted Date
2015-07-16
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
12
Registration Number
NCT02354027

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: SHR3824
Drug: Placebo
First Posted Date
2015-01-26
Last Posted Date
2015-02-03
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
30
Registration Number
NCT02346175

A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor

Phase 2
Conditions
Gastrointestinal Stromal Tumor
Interventions
Drug: Famitinib
First Posted Date
2015-01-13
Last Posted Date
2018-04-17
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
88
Registration Number
NCT02336724
Locations
🇨🇳

Nanjing Bayi Hospital, Nanjing, Jiangsu, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy